Oral semaglutide vs traditional diabetes medicine: how they actually differ

You're already on metformin and wondering where a semaglutide tablet fits

Picture the common starting point. You've taken metformin for a while, your numbers are steadier than they were, but the scales haven't shifted and you've read that a semaglutide tablet might help. That's a fair question, and the honest answer starts with what each medicine was built to do.

Metformin is a long-established first-line drug for type 2 diabetes. It mainly reduces how much glucose your liver releases and helps your body respond better to insulin. It's cheap, well understood, and generally weight-neutral or mildly weight-lowering. It was never designed as a weight-loss treatment, though.

Oral semaglutide is a different animal. As a GLP-1 receptor agonist it slows how quickly your stomach empties and acts on appetite signalling in the brain, so many people feel full sooner and eat less without white-knuckling it. The NHS explains the GLP-1 mechanism plainly in its patient guide to semaglutide. The two can sometimes be used alongside each other for diabetes, but that's a clinical decision, not a swap you make yourself.

One thing worth clearing up gently: a semaglutide tablet is not simply a stronger metformin. They belong to different drug families and answer different questions. If your priority is weight management specifically, the licensed tablet for that is Wegovy in tablet form, and it's worth understanding that route on its own terms rather than as an upgrade to what you already take.

• Rybelsus vs semaglutide, explained
• The Wegovy tablet route

Which of these medicines is licensed for weight loss, and which aren't

This trips people up more than any dose or side effect, so let's be precise. Semaglutide is the active ingredient in three UK products, and they are not interchangeable.

Wegovy tablets (oral semaglutide) became the first oral GLP-1 medicine licensed in the UK for weight management, approved by the MHRA in June 2026. Rybelsus contains the same molecule but is licensed for type 2 diabetes, not weight loss. Ozempic is the injectable semaglutide licensed for type 2 diabetes as well, and again not for weight loss. You can read the MHRA's public position on GLP-1 medicines in its guidance titled GLP-1 medicines for weight loss and diabetes.

Traditional diabetes medicines sit in a separate box entirely. Metformin, sulfonylureas such as gliclazide, and insulin are all licensed to manage blood sugar in diabetes. Some can affect weight, but none is licensed or prescribed as a weight-loss treatment on its own.

So if a page or a seller implies you can order Rybelsus or Ozempic to lose weight, that's a licensing mismatch worth spotting. If weight is the goal, the tablet designed and licensed for it is the Wegovy 25mg weight-management tablet. If you're currently on a diabetes semaglutide and weight is now the aim, the sensible step is a proper review, which is exactly what moving from Rybelsus toward Wegovy involves.

• Semaglutide tablets vs Ozempic
• Explore weight-loss treatment options

How the tablet is taken compared with everyday diabetes routines

The practical rhythm differs, and that surprises people. Metformin usually goes with or after meals to settle the stomach, often twice a day. A sulfonylurea is typically timed with breakfast. Insulin follows its own injection schedule set by your team.

Oral semaglutide is fussier about timing on purpose. It's taken once daily, first thing, on an empty stomach with a small sip of plain water. Then you wait at least half an hour before food, coffee, other drinks or other tablets. Miss that window and absorption drops. It's the tablet before the kettle goes on, not with your cereal.

Dose-wise, the weight-management tablet follows a stepped path the prescriber controls: it begins low and builds gradually, with a minimum of a month at each level before reaching the 25mg maintenance dose. That slow climb is deliberate, giving your system time to adjust and keeping early nausea in check. We won't print a personal schedule here because that's the prescriber's call, guided by the product's licensed leaflet.

The upside for daily life is real. There's no refrigeration to plan around and no needle, so travel and work days are simpler than with an injection or with insulin. The trade-off is discipline: the empty-stomach half hour has to become a habit, otherwise the medicine can't do its job. For most people that's a fair swap, and the tablet overview sets out how the routine settles into a normal morning.

What the trial evidence shows on weight, and what it doesn't

Numbers help here, so long as we're honest about what they measure. Traditional diabetes medicines were trialled mainly on blood sugar, not body weight, so comparing headline weight figures across the two groups isn't like-for-like.

For oral semaglutide as a weight treatment, the clearest UK figures come from the OASIS 4 trial: over 64 weeks, participants lost roughly 13.6% of body weight on average against about 2.4% on placebo, alongside diet and activity changes. Among those who stayed fully adherent to treatment, the figure rose to around 17%. That adherence gap is the important footnote, and it circles straight back to the empty-stomach routine.

NICE's appraisals set the framework for how semaglutide is used in the NHS; its recommendation for semaglutide (TA875) is a useful reference point for the injection pathway, and the tablet would need its own appraisal before any NHS availability. What the evidence doesn't claim is a guaranteed result for you personally, which is why individual assessment matters.

Side effects: where the two families overlap and where they part

Both routes can unsettle the gut, but the patterns differ. Metformin's classic early niggles are loose stools and stomach discomfort, usually easing as your body adjusts. Sulfonylureas and insulin carry a real risk of low blood sugar, which GLP-1 medicines used alone generally don't.

Oral semaglutide's most common effects are gastrointestinal too: nausea, occasional vomiting, changes to bowel habit, indigestion, sometimes fatigue or headache. In the OASIS 4 trial these hit around three-quarters of the semaglutide group versus roughly four in ten on placebo, but they were mostly mild to moderate and tended to fade after starting or a dose step. The slow dose build exists largely to soften them.

There's a rarer signal worth naming clearly. In January 2026 the MHRA reminded prescribers and patients that acute pancreatitis, though infrequent, can occur with GLP-1 medicines; severe stomach pain that spreads through to your back, with or without being sick, needs urgent medical attention. That advice sits in the MHRA Drug Safety Update series.

Suspected side effects from any of these medicines can be reported through the Yellow Card scheme. None of this is a reason for alarm; it's simply why a prescription medicine belongs with a clinician who knows your history rather than picked off a shelf. Our prescribers weigh these profiles against your other medicines before anything is agreed.

Getting these medicines in the UK: NHS routes and the private option

Traditional diabetes medicines are prescribed routinely on the NHS by GPs, so if you have type 2 diabetes, metformin and its relatives usually cost only a standard prescription charge. That's the well-trodden path.

The weight-management semaglutide tablet is different at launch. It isn't on the NHS yet, because a NICE appraisal would be needed first, so at present it's available privately on prescription. GLP-1 injections have phased NHS access under strict criteria that are widening over time, but waiting lists through specialist services are commonly long.

A private route through a regulated pharmacy is the alternative for people who don't meet those criteria or don't want to wait. The one non-negotiable is legitimacy. Any online pharmacy should be checkable on the GPhC register, and you can look up ours directly. Red flags are sellers offering these medicines without a prescription, social-media accounts, prices well below the market, and discount codes from unknown sources; the MHRA has seized around 20 million doses of illegally traded weight-loss medicines. At nume, your order is dispatched the same working day once approved and delivered free the next working day by DPD in plain packaging, with no subscription attached. You can read more about who we are and how we work.

• What the tablet costs and what's included
• Meet the clinician behind our reviews

Deciding between the routes with a prescriber, not a checkout

Here's the part that resists a neat verdict. The right choice depends on why you're treating, what else you take, how your body handles GI effects, and whether daily discipline or a weekly rhythm suits your life better. Someone whose main issue is glucose control may be best served by their existing diabetes medicines. Someone whose priority is weight, and who can commit to the morning routine, may be better matched to the licensed tablet.

What we won't do is pretend one is universally superior. A GLP-1 tablet is not a replacement for insulin in someone who needs insulin, and metformin is not a weight-loss drug dressed up as one. These are different tools for different jobs, and the overlap is narrower than the marketing around them suggests.

At nume, a GPhC-registered Independent Prescriber reads your consultation the same day, checks your history and current medicines, verifies your identity and weight, and only then decides whether a treatment is suitable. There's no algorithm making that call. If we don't think a medicine is right for you, we'll say so.

Ultimately, which suits you is a clinical decision our prescribers make with you. If you'd like that conversation, you can start your free consultation whenever you're ready, or read our general FAQs first. Questions about your specific situation are welcome through our support team.

Related questions we've answered

• How Rybelsus compares with semaglutide generally
• Semaglutide tablets set against Ozempic
• Moving from Rybelsus toward Wegovy
• The cost of the Wegovy tablet route